Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced hospitalizations for heart failure and death versus other type-2 diabetes medicines
Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced risk of hospitalization for heart failure by 39% and all-cause mortality by 51%
CVD-REAL data are presented at the American College of Cardiology 66th Annual Scientific Session
LYNPARZA™ (olaparib) Phase III SOLO-2 data demonstrated progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
LYNPARZA reduced risk of disease progression by 70% with an investigator-assessed progression-free survival of 19.1 vs 5.5 months with placebo
Blinded independent central review showed significant progression-free survival of 30.2 months vs 5.5 months with placebo
LYNPARZA tablets demonstrated a safety profile generally consistent with previous studies
FDA approves once-daily QTERN® (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
QTERN fixed-dose combination will provide an additional oral medicine option for patients taking FARXIGA® (dapagliflozin) to improve blood sugar level
AstraZeneca (NYSE:AZN) today announced that the US Food and Drug Administration (FDA) has approved once-daily QTERN® (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
LYNPARZA™ (olaparib) meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer
LYNPARZA provided a statistically-significant improvement in progression-free survival compared to chemotherapy
First positive randomized trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer
AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.
Latest AZ&You Blog Articles
Our Favorites from 2016 – Highlights of the AZ&You Blog
Throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. From the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over.
Stigma, Genetics and Hope: 11 Years with Lung Cancer
In 2005, Melissa Crouse was diagnosed with lung cancer and given three to five years to live. Eleven years later, Melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. Melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.
What Does the New CancerLinQ Discovery Initiative Mean for the Future of Patient Care?
By Kevin Fitzpatrick, CEO, CancerLinQ LLC
This is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. Imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care.
Personalized Healthcare: What It Means and Why It Matters
When it comes to cancer treatment, one size does not fit all. Of the estimated 1.6 million Americans who will be diagnosed with cancer in 2016, no two will be exactly the same. More and more, we’re hearing (and using) buzzwords to this effect: Personalized healthcare. Precision medicine. Targeted therapy.
What Getting ON IT Means to Me for American Diabetes Month®
By Dr. Phil McGraw
As someone who has lived with type 2 diabetes for more than 25 years, I understand the day-to-day issues that accompany managing a lifelong disease. It’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience.
How the Type 2 Diabetes Patient Community is Unifying their Voice Online
While online conversations about diabetes are on the rise and people with diabetes have cultivated the Diabetes Online Community (#DOC) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. To help strengthen and elevate the voices of type 2 diabetes advocates, AstraZeneca recently hosted members of the type 2 community for DiabetesLinkup: In It 2gether.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.